Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients ...Middle East

PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary...

Hence then, the article about soligenix announces topline results from its phase 3 clinical trial of sgx942 for the treatment of oral mucositis in head and neck cancer patients was published today ( Tuesday 22/12/2020 - 02:46 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients )

Also on site :

• Another French museum robbed despite ‘special attention’ after Louvre heist
• "Kill him": Phil Salt reveals Virat Kohli's advice amid India-England series
• Ronaldo’s last World Cup? We will see, says Portugal star before Spain clash